MannKind to Present at the Jefferies Global Healthcare Conference
Rhea-AI Summary
MannKind (Nasdaq: MNKD) announced that CEO Michael Castagna and CFO Chris Prentiss will present updates at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 6:30 AM ET / 11:30 AM GMT. A live audio webcast will be available on the company's investor site and recorded versions will be accessible on the same site for approximately 90 days after the conference.
Investors can access the live and recorded sessions via the company’s events and presentations page at the investor relations website.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial Officer, are scheduled to present and share updates during the Jefferies London Healthcare Conference on Wednesday, November 19, at 6:30 am ET/11:30 am GMT.
The link to the live audio webcast of the session is available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
For MannKind: Investor Relations Ana Kapor Email: ir@mnkd.com Media Relations Christie Iacangelo Email: media@mnkd.com